Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

Date

30 Sep 2019

Session

Poster Display session 3

Presenters

Daan Hurkmans

Citation

Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253

Authors

D.P. Hurkmans1, E.A. Basak2, T. van Dijk2, D. Mercieca3, M.W.J. Schreurs4, A.J.M. Wijkhuijs4, S. Bins5, E. Oomen-de Hoop6, R. Debets2, M. Joerger7, A. Odink8, A.A.M. Van der Veldt9, C.H. Van Der Leest10, J.G. Aerts11, R.H.J. Mathijssen6, S.L. Koolen12

Author affiliations

  • 1 Medical Oncology And Pulmonary Medicine, Erasmus MC Cancer Institute, 3015 GD - Rotterdam/NL
  • 2 Medical Oncology, Erasmus University Medical Center, 3015 GD - Rotterdam/NL
  • 3 Pulmonary Medicine, Erasmus University Medical Center, 3015 GD - Rotterdam/NL
  • 4 Immunology, Erasmus University Medical Center, 3015 GD - Rotterdam/NL
  • 5 Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 3075EA - Rotterdam/NL
  • 6 Medical Oncology, Erasmus MC Cancer Institute, 3015 GD - Rotterdam/NL
  • 7 Medical Oncology & Hematology, Kantonsspital St. Gallen, 9007 - St. Gallen/CH
  • 8 Radiology & Nuclear Medicine, Erasmus University Medical Center, 3015 GD - Rotterdam/NL
  • 9 Medical Oncology And Radiology & Nuclear Medicine, Erasmus University Medical Center, 3015 CE - Rotterdam/NL
  • 10 Pulmonary Medicine, Amphia Ziekenhuis-location Molengracht, 4818 CK - Breda/NL
  • 11 Pulmonary Medicine, Erasmus University Medical Center, 3015 CE - Rotterdam/NL
  • 12 Medical Oncology And Hospital Pharmacy, Erasmus University Medical Center, 3015 CE - Rotterdam/NL
More

Resources

Background

Nivolumab is currently administered in a weight-based or fixed-flat dosing regimen. Approved fixed-flat dosing regimens have been solely based on simulations from dose-finding clinical trials. For patients with non-small cell lung cancer (NSCLC), a potential exposure-response relationship has recently been reported, suggesting that nivolumab dosing needs further optimization. In this study, we determined nivolumab pharmacokinetics (PK) and assessed the relationship between nivolumab clearance (CL) and tumor response in patients with NSCLC, melanoma, and renal cell cancer (RCC).

Methods

In this prospective observational cohort study (MULTOMAB trial; Dutch Trial Registry NL6828), individual estimates of nivolumab CL and the impact of baseline covariates were determined using population-PK (PPK) modeling. The study was approved by the independent ethics committee (MEC 16-011). All patients provided written informed consent. Stratified by tumor type, CL was related to best overall response (RECIST v1.1) using ANOVA and post-hoc samples t-test.

Results

In total 1,715 nivolumab serum concentrations were analyzed from 221 patients who were treated with monotherapy nivolumab (NSCLC n = 158; melanoma n = 48; RCC n = 14; mesothelioma n = 1). The baseline parameters gender, body surface area (BSA), and serum albumin had a significant effect on nivolumab CL and were internally validated in the PPK model. Women had 22% lower CL than men, Patients with BSA > 2.2 m2 or with baseline albumin <37.5 g/L had >20% higher CL than the population mean. For NSCLC, CL was 42% higher in patients with progressive disease (mean: 0.24; 95%CI: 0.22-0.27 L/day) compared to patients with partial/complete response (0.17; 0.15-0.19). Although a similar trend was observed in RCC, no CL-response relationship was observed in melanoma patients.

Conclusions

We generated the first real-world PPK model of nivolumab, in which covariate analysis revealed a significant effect of gender, BSA, and albumin on nivolumab CL. A significant CL-response relationship was observed in patients with NSCLC, but not in patients with melanoma. Individualized dosing regimens might therefore increase nivolumab efficacy in patients with NSCLC.

Clinical trial identification

MULTOMAB trial; Dutch Trial Registry NL6828.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

A.A.M. Van der Veldt: Advisory / Consultancy: BMS. J.G. Aerts: Advisory / Consultancy: BMS. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings